-

Amneal to Participate at Upcoming Investor Conferences in May

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its investor relations or management team will attend the following investor conferences:

RBC Healthcare Conference
May 17, 2022
Investor Relations Hosted Meetings
New York, New York

UBS Healthcare Conference
May 25, 2022
Investor Relations Hosted Meetings
New York, New York

Barclays CEO Call Series
May 27, 2022
Fireside Chat – 10:00am Eastern Time

About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.

Contacts

Tony DiMeo
Head of Investor Relations
Anthony.DiMeo@amneal.com

Industry:

Amneal Pharmaceuticals, Inc.

NYSE:AMRX
Release Versions
English

Contacts

Tony DiMeo
Head of Investor Relations
Anthony.DiMeo@amneal.com

More News From Amneal Pharmaceuticals, Inc.

Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA”) for calcium gluconate in sodium chloride injection, 1000 mg/50 mL and 2000 mg/100 mL. This injectable product is currently on the U.S. FDA shortage product list. The product approval received the FDA’s Competitive Generic Therapy (“CGT”) designation with 180-...

 Amneal Receives First Product Approval in China

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received its first product approval in China. Sevelamer carbonate was approved and is expected to launch shortly. In addition, the Company expects to launch oseltamivir phosphate in China this year as well, upon approval. In total, Amneal has 6 products pending review in China with more product registrations planned over time. Since 2019, the Company has collaborated...

 Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for lisdexamfetamine dimesylate capsules, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. Lisdexamfetamine dimesylate capsules is a generic version of Vyvanse®. This ADHD product is currently on the U.S. FDA shortage product list, and Amneal has already begun sup...
Back to Newsroom